Risk for Death From Prostate Cancer Low With Guideline Care for Nonmetastatic Disease
MONDAY, July 14, 2025 -- Men with nonmetastatic prostate cancer receiving guideline-concordant care have a much higher risk for death from causes other than prostate cancer, according to a study published online July 10 in the Journal of the National Comprehensive Cancer Network.
Pietro Scilipoti, M.D. from Uppsala University in Sweden, and colleagues followed men with nonmetastatic prostate cancer, registered in the National Prostate Cancer Register of Sweden from 2000 to 2020, who received primary treatment according to the National Comprehensive Cancer Network (NCCN) Guidelines until Dec. 31, 2022. The risk for mortality from prostate cancer and other causes was estimated up to 30 years according to risk category and life expectancy.
Overall, 62,839 men received primary treatment according to the NCCN Guidelines. The researchers found that per risk category, the simulated 15-year prostate cancer mortality ranged from 5.5 to 22 percent in men with low-risk and very high-risk cancer, respectively. Simulated 30-year prostate cancer mortality varied from 12 to 30 percent in men with low-risk and very high-risk cancer, respectively, while death from other causes varied from 77 to 63 percent.
"Our data support adherence to guideline recommendations for treatment of prostate cancer," Scilipoti said in a statement. "If guideline-recommended treatment is used, most people with prostate cancer will live for many years after diagnosis. That includes active surveillance as an excellent treatment strategy for appropriately selected people."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Higher Tattoo Exposure Linked to Reduced Melanoma Risk
MONDAY, Sept. 29, 2025 -- Higher tattoo exposure may be associated with reduced melanoma risk, according to a study published online Aug. 21 in the Journal of the National Cancer...
Antithymocyte Globulin Cuts Loss of β-Cell Function in Type 1 Diabetes
MONDAY, Sept. 29, 2025 -- Antithymocyte globulin (ATG) 2.5 and 0.5 mg/kg reduces loss of β-cell function in young people with recent-onset type 1 diabetes, according to a...
Loss of Therapeutic Benefit Seen After Stopping Baricitinib in Type 1 Diabetes
MONDAY, Sept. 29, 2025 -- Two-year follow-up shows a loss of therapeutic benefit when baricitinib treatment is stopped in type 1 diabetes (T1D), according to a study presented at...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.